Study on Belantamab Mafodotin and Nirogacestat for Treating Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of multiple myeloma.
• Have received at least three previous treatments for multiple myeloma, including specific types of drugs.
• If you had a stem cell transplant, it must have been over 100 days ago, and you should not have any active infections.
• Have a performance status score of 0 or 1, or 2 if due to bone issues from multiple myeloma.
• Have measurable disease based on specific medical tests.
• If you have tested positive for Hepatitis B, certain conditions must be met to participate.
• Can be on low-dose steroids or certain other medications.

Exclusion Criteria

• Have current eye disease, except for mild conditions.
• Have heart-related health risks.
• Have allergies to drugs similar to belantamab mafodotin or its components.
• Have active infections needing treatment.
• Have used other monoclonal antibodies recently or had certain cancer treatments within the last few weeks.
• Have had a recent allogeneic transplant or CAR-T therapy.
• Have had major surgery recently, except for bone-stabilizing surgery.
• Have had investigational treatments recently.
• Have severe side effects from previous treatments that led to stopping those treatments.
• Have had a blood transfusion recently.
• Have received live vaccines recently or plan to during the study.
• Have active kidney conditions affecting safety.
• Have HIV unless specific conditions are met.
• Have uncontrolled digestive or skin diseases.
• Have conditions causing low levels of certain minerals that can't be corrected.
• Have used a gamma secretase inhibitor before.
• Are taking certain strong medications that affect how the body processes drugs.